医学博士

日本内科学会認定医
日本リウマチ学会専門医
日本アレルギー学会専門医

日本内科学会
日本リウマチ学会
日本アレルギー学会
日本免疫学会
American College of Rheumatology
The Korean Association of Immunobiologists
Korean Society for Molecular and Cellular Biology
The Korean Academy of Asthma, Allergy and Clinical Immunology

2006年

The Association for Preventive Medicine of Japan, Research Resident Grant
Bio Technology R&D Program, Korea (20090081756)

Basic Science Research Program through the National Research Foundation of Korea (NRF)　funded by the Ministry of Education, Science and Technology (2012R1A1A3015334)

Basic Science Research Program through the National Research Foundation of Korea (NRF)　funded by the Ministry of Education, Science and Technology (2015R1A1A3A04001051)

Pioneer Research Center Program through the National Research Foundation of Korea funded　by the Ministry of Science, ICT & Future Planning (2015-001937 and 2015-001923) ​

2005年

Japan Rheumatism Foundation, Research Grant

2005年

Mochida Memorial Foundation for Medical and Pharmaceutical Research, Research Grant

2005年

Fellows Award for Research Excellence (FARE) sponsored by the Scientific Directors, NIH Office of Education, NIH Office of Research on Women’s Health, as well as the NIH Fellows Committee (FELCOM) ​

2004年

Cytokine Paper of the Year Award, Cytokine Interest Group, NIH

• Yoon JH, Sudo K, Kuroda M, Kato M, Lee IK, Han JS, Nakae S, Imamura T, Kim JR, Ju JH, Kim DK, Matsuzaki K, Weinstein M, Matsumoto I, Sumida T, Mamura M.
  Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in TH17 differentiation.
  Nature Commun. doi:10.1038/ncomms8600, 2015, IF: 11.47.
• Lee YS, Park JS, Jung SM, Kim SD, Kim JH, Lee JY, Jung KC, Mamura M, Lee S, Kim SJ, Bae YS, Park SH.
  Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide.
  EMBO Mol Med. doi: 10.15252/emmm.201404653, 2015, IF: 8.665.
• Kwak JY, Mamura M, Barlic-Dicen J, Grage-Griebenow E.
  Editorial review: Pathophysiological Roles of Cytokine-Chemokine Immune Network.
  J Immunol Res. Volume 2014 (2014), Article ID 615130, IF: 2.934.
• Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, Oh BC, Sumida T, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M.
  Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
  EMBO Mol Med. 11:1720-1739, 2013, IF: 8.665.
• Kim OH, Kang GH, Noh H, Cha JY, Lee HJ, Yoon JH, Mamura M, Nam JS, Lee DH, Kim YA, Park YJ, Kim H, Oh BC.
  Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes. Mol Cells. 36:432-438, 2013, IF: 2.090.
• Chon SJ, Kim SY, Cho NR, Min DL, Hwang YJ, Mamura M.
  Association of variants in PPARγ2, IGF2BP2, and KCNQ1 with a susceptibility to gestational diabetes mellitus in a Korean population.
  Yonsei Med J. 54:352-357, 2013, IF: 1.287.
• Kang YJ, Shin JW, Yoon JH, Oh IH, Lee SP, Kim SY, Park SH, Mamura M.
  Inhibition of erythropoiesis by Smad6 in human cord blood hematopoietic stem cells.
  Biochem Biophys Res Commun. 13;423:750-756, 2012, IF: 2.297 Highlighted by Hematopoiesis News 3.24.
  (http://connexoncreative.com/publications/archives/HN324.aspx)
• Park HY, Wakefield LM, Mamura M.
  Regulation of tumor immune surveillance and tumor immune subversion by TGF-?.
  Immune Network. 9:122-126, 2009.
• Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR, Kim WJ, Han JY, Hong SS, Park SH, Lee SJ, Kim IH, Lee CR, Kim DK, Mamura M, Kim SJ, Suh JK.
  IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie’s disease.
  J Sex Med. 6:1284-1296, 2009, IF: 3.151.
• Zhang LW, Piao S, Choi MJ, Shin HY, Jin HR, Kim WJ, Song SU, Han JY, Park SH, Mamura M, Kim SJ, Ryu JK, Suh JK.
  Role of increased penile expression of transforming growth factor-beta1 and activation of the Smad signaling pathway in erectile dysfunction in streptozotocin-induced diabetic rats.
  J Sex Med. 5:2318-2329, 2008, IF: 3.151.
• Ishii W, Ito S, Kondo Y, Tsuboi H, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T, Okoshi Y, Hasegawa Y, Kojima H, Sakashita S, Aita K, Noguchi M.
  Intravascular large B-cell lymphoma with acute abdomen as a presenting symptom in a patient with systemic lupus erythematosus.
  J Clin Oncol. 26:1553-1555, 2008, , IF: 18.428.
• Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T.　
  Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
  Arthritis Rheum. 58:754-763, 2008, IF: 7.764.
• Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T.
  Interleukin-17 gene expression in patients with rheumatoid arthritis.
  Mod Rheumatol. 18:15-22, 2008, IF: 2.397.
• Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang Y, Lawrence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.
  TGF-subverts the adaptive immune system into directly promoting tumor growth through an IL-17-mediated mechanism.
  Cancer Res. 68:3915-3923, 2008, IF: 9.329.
• Nam JS, Terabe M, Mamura M, Yang Y, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.
  Anti-TGF-antibody monotherapy suppresses metastasis through a combination of small effects on multiple cellular compartments in a breast cancer model.
  Cancer Res. 68:3835-3843, 2008, IF: 9.329.
• Flanders KC, Ho BM, Arany PR, Stuelten C, Mamura M, Paterniti MO, Sowers A, Mitchell JB, Roberts AB.
  Absence of Smad3 induces neutrophil migration following cutaneous irradiation: possible contribution to subsequent radioprotection.
  Am J Pathol. 173:68-76, 2008, IF: 4.591.
• Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT, Wakefield LM.
  Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast Cancer xenograft model.
  Cancer Res. 67:8643-8652, 2007, IF: 9.329.
• Hayashi T, Matsumoto I, Yasukochi T, Mamura M, Goto D, Ito S, Tsutsumi A, Sumida T.
  Biased usage of synovial immunoglobulin heavy chain variable region 4 by the anti-glucose-6-phosphate isomerase antibody in patients with rheumatoid arthritis.
  Int J Mol Med. 20:247-253, 2007, IF: 2.088.
• Enami T, Suzuki T, Ito S, Yoshimi A, Sugihara M, Mamura M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
  Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.
  Intern Med. 46:1033-1037, 2007, IF: 0.904.
• Sugihara M, Tsutsumi A, Suzuki E, Wakamatsu E, Suzuki T, Ogishima H, Hayashi T, Chino Y, Ishii W, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T.
  Effects of infliximab therapy on gene expression levels of TNF-alpha, TTP, TIA-1 and HuR in patients with rheumatoid arthritis.
  Arthritis Rheum. 56:2160-2169, 2007, IF: 7.764.
• Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
  Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease.
  Intern Med 46:771-774, 2007, IF: 0.904.
• Yamada H, Ishii W, Ito S, Iwanami K, Ogishima H, Suzuki T, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
  Sarcoid myositis with muscle weakness as a presenting symptom.
  Mod Rheumatol 17:243-246, 2007, IF: 2.397.
• Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group (participated as a member of investigators).
  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
  Lancet. 368:1155-1163, 2006, IF: 45.217.
• Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, Ito S, Tsutsumi A, Sumida T.
  Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjogren’s syndrome.
  Arthritis Rheum. 54:3476-3484, 2006, IF: 7.764.
• Suzuki E, Tsutsumi A, Sugihara M, Mamura M, Goto D, Matsumoto I, Ito S, Ikeda K, Ochiai N, Sato Y, Sumida T.
  Expression of TNF-alpha, tristetraprolin, T-cell intracellular antigen-1 and Hu antigen R genes in synovium of patients with rheumatoid arthritis.
  Int J Mol Med. 18:273-278, 2006, IF: 2.088.
• Kim BG, Li C, Qiao W, Mamura M, Kasperczak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, Kim SJ, Fu XY, Deng C, Letterio JJ.
  Smad4 signalling in T cells is required for suppression of gastrointestinal cancer.
  Nature. 441:1015-1019, 2006, IF: 41.456.
• Tsutsumi A, Hayashi T, Chino Y, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T.
  Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays.
  Mod Rheumatol. 16:158-164, 2006, IF: 2.397.
• Ito S, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
  Diagnosis of chlamydia-induced reactive arthritis.
  Intern Med. 45:37, 2006, IF: 0.904.
• Kitagawa M, Goto D, Mamura M, Matsumoto I, Ito S, Tsutsumi A, Sumida T.
  Identification of three novel peptides that inhibit CD40-CD154 interaction.
  Mod Rheumatol. 15(6):423-426, 2005, IF:2.206.
• Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA.
  TGF-beta1 production by CD4(+)CD25(+) regulatory T cells is not essential for suppression of intestinal inflammation.
  Eur J Immunol. 35:2886-2895, 2005, IF: 4.034.
• Mamura M, Wolfraim LA, Fernandez TM, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ.
  Loss of Smad3 in Acute T-Cell Lymphoblastic Leukemia.
  N Engl J Med. 351:552-559, 2004. Equal contribution, IF: 55.873.
• Mamura M, Lee WK, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letteio JJ.
  CD28 disruption exacerbates inflammation in Tgf-b1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-1. Blood. 103:4594-4601, 2004, IF: 10.452.
• Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA.
  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
  J Exp Med. 198:1741-1752, 2003, IF: 12.515.
• Kim HT, Kim BC, Kim IY, Mamura M, Seong DH, Jang JJ, Kim SJ.
  Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through Cleavage of BAD in TSU-PR1 human cancer cells.
  J Biol Chem. 277:32510-32515, 2002, IF: 4.573.
• Kim BC, Mamura M, Ambudkar IS, Choi KS, Kim SJ.
  Tumor necrosis factor induces apoptosis in hepatoma cells by increasing Ca(2+) release from the endoplasmic reticulum and suppressing Bcl-2 expression.
  J Biol Chem. 277:31381-31389, 2002, IF: 4.573.
• Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, Shevach EM.
  CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of TGF-1 production and responsiveness.
  J Exp Med. 196:237-246, 2002, IF: 12.515.
• Yang Y, Dukhanina O, Tang B, Mamura M, Letterio J.J, MacGregor J, Patel SC, Khozin S, Liu Z, Green JE, Anver MR, Merlino G, Wakefield LM.
  Lifetime exposure to a soluble TGF-antagonist protects mice against metastasis without adverse side effects.
  J Clin Invest. 109:1607-1615, 2002, IF: 13.215.
• Kim BC, Mamura M, Choi KS, Calabretta B, Kim SJ.
  Transforming growth factor beta1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells.
  Mol Cell Biol.:1369-1378, 2002, IF: 4.777.
• Inagaki Y, Mamura M, Kanamaru Y, Greenwel P, Nemoto T, Takehara K, ten Dijke P, Nakao A.
  Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells.
  J Cell Physiol. 187:117-123, 2001, IF: 3.839.
• Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP.
  Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.
  Proc Natl Acad Sci U S A. 98:2587-2592, 2001, IF: 9.674
• Kanamaru Y, Nakao A, Mamura M, Suzuki Y, Shirato I, Okumura K, Tomino Y, Ra C.
  Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis.
  J Immunol. 166:2818-2823, 2001, IF: 4.922.
• Mamura M, Nakao A, Goto D, Kato M, Saito Y, Iwamoto I.
  Ligation of the T cell receptor complex results in activation of Smad2 in T lymphocytes.
  Biochem Biophys Res Commun. 268:124-127, 2000, IF: 2.297.
• Inaba M, Kurasawa K, Mamura M, Kumano K, Saito Y, Iwamoto I.
  Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells.
  J Immunol. 163:1315-1320, 1999, IF: 4.922.
• Tsukahara K, Nakao A, Hiraguri M, Miike S, Mamura M, Saito Y, Iwamoto I.
  Tumor necrosis factor-a mediates anti-apoptotic signals partially via p38 MAP kinase activation in human eosiophils. Int Arch Allergy Immunol.
  120 Suppl 1:54-59, 1999, IF: 2.673.